HHS-NIH-NIAID-BAA2020-1 Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections, and Emerging Infectious Diseases Supports development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 , including optimization, preclinical (investigational new drug-enabling), and clinical trials that include Phase I and Phase II studies. Due Date: April 9, 2020, by 3 p.m. Eastern Time Read more on…

HHS-NIH-NIAID-BAA2020-1 Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases Supports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp., Pseudomonas aeruginosa, Francisella tularensis, Yersinia pestis, and E. coli, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (e.g., Eastern Equine Encephalitis) and bunyaviruses (e.g., Rift Valley Fever Virus). Due Date: April 9, 2020, by 3 p.m. Eastern Time Learn more about this opportunity…

HHS-NIH-NIAID-BAA2020-1 Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases Supports advancing the development of novel, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness. Number of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined). Due Date: April 9, 2020, by 3 p.m. Eastern Time…

Innovators within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in grant funding; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies. The submission deadline is 24 April 2020. Please visit the JLABS website for more information.

Under this EZ BAA, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, will review concise abstract submissions for development funding of 2019-nCoV molecular diagnostics. The diagnostics must utilize platforms already cleared by the U.S. Food and Drug Administration, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award. This area of interest will be open for…

This CDC Center for Global Health is working to partner and build laboratory and biosurveillance capacity globally under this funding effort (CDC-RFA-GH20-2109) to reduce the risks of emerging infectious diseases and strengthen public health response to outbreaks. Grants are available to all types of organizations (government, academic, nonprofit, industry, etc.). Supported activities include: Assessing capacity of national reference, provincial and district labs Identifying lab system focal points, defining a tiered services structure Developing and implementing strategic lab plans Mapping regional…